Reversible airway obstruction as a result of bronchial hyper-reactivity, airway inflammation, mucous plugging, and SM hypertrophy. [The airway obstruction is due to inflammation of the bronchial wall, constriction of the bronchiolar SM and increased mucous secretion.]
Short acting B2 agonists (SABAs) → Albuterol, Pirbuterol, Terbutaline [used for acute relief of bronchospasm]
Long acting B2 agonists (LABAs) → Salmeterol, Formoterol
*B2 agonists increase intracellular cAMP resulting in relaxation of the bronchial smooth muscle and subsequent bronchodilation. When administering these drugs they are inhaled minimizing their systemic effects b/c B2 agonists are poorly absorbed into the circulation via the lungs. [available via MDI (metered-dose inhalers), spaces of VHC (valved holding chambers)]
A small percentage of the population may have a genetic predisposition (polymorphism at the b2 receptor) that causes worsened asthma → exacerbations → death. ??
Tremors, tachycardia arrhythmias, hyperglycemia, tolerance, paradoxical bronchospasm
Parasympathetic stimulation causes bronchial constriction and mucous secretion. Anticholinergics are used to block the muscarinic receptors in the smooth muscles and maintain bronchial dilation of the airway.
2. Use with caution in pts with Glaucoma, BPH, bladder neck obstruction
Increase levels → Cimetidine, erythromycin, ciprofloxacin
Decrease levels → phenytoin, phenobarbitone, carbamazepine
Tremor, insomnia, GI distress, nausea, hypokalemia, hyperglycemia, seizures, arrhythmias
Acute exacerbations → systemic steroids when attack is severe
Maintenance therapy → low dose inhalation corticosteroids suppress inflammation and reduce the risk of exacerbation
*use in both acute and maintenance asthma management. Most inhaled corticosteroid goes in to the stomach to be metabolized.
Omalizumab – this is an anti-IgE antibody that is administered parenterally. It binds to IgE on sensitized mast cells and prevents their activation and thus release of LTs and other mediators. It is used in the prophylactic management in asthmatic patients of inadequate control above the age of 12. There is a slim risk of the development of anaphylaxis.
Cough, oral thrush, dysphonia
Dexamethasone and prednisone → life saving steroid in status asthmaticus
Oral glucocorticoids → used in exacerbations with incomplete response to B2 agonists
*Adverse effects → abnormal glucose metabolism, increased appetite, weight gain, HTN, adrenal suppression [minimize systemic corticosteroid use to a few days]
Zileuton – elevated liver enzymes
Zafirlukast and Montelukast – development of vasculitis and systemic eosinophilia similar to Churg-Strauss syndrome (p-anca)
Infrequent laryngeal edema, cough, wheezing and Nedocromil may cause an unpleasant taste